- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | METIS TECHBIO-P Forms Strategic Partnership with Eli Lilly and Company to Advance Next-generation Tissue-specific LNP Delivery Technology | 13 | AASTOCKS | ||
| 19.10. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ENTERED STRATEGIC COLLABORATION WITH LILLY TO ADVANCE NEXT-GENERATION TISSUE-SPECIFIC LNP ... | 2 | HKEx | ||
| METIS TECHBIO Aktie jetzt für 0€ handeln | |||||
| 29.09. | METIS TECHBIO-P (07666): 2026 INTERIM REPORT | 4 | HKEx | ||
| 04.09. | METiS TechBio revenue surges on licensing deal | 2 | China Daily | ||
| 25.08. | METIS TECHBIO-P (07666): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 12.08. | METIS TECHBIO-P (07666): DATE OF BOARD MEETING | 1 | HKEx | ||
| 04.08. | METIS TECHBIO-P (07666): (1) APPOINTMENT OF JOINT COMPANY SECRETARY; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | - | HKEx | ||
| 03.08. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE ... | 2 | HKEx | ||
| 31.07. | METIS TECHBIO-P (07666): (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE ... | 2 | HKEx | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | 2 | FierceBiotech | ||
| 30.06. | Metis TechBio seals $1.62b global licensing deal with Boulevard Bio | 1 | China Daily | ||
| 30.06. | METiS TechBio vergibt Lizenz für Wirkstoffkandidaten in 1,6-Milliarden-Dollar-Deal | - | Investing.com Deutsch | ||
| 30.06. | METiS TechBio licenses drug candidate to Boulevard Bio for $1.6B | 3 | Investing.com | ||
| 30.06. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US$1.6 BILLION | 2 | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 12.06. | METIS TECHBIO-P (07666): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF ... | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 62,41 | -0,87 % | Tempus AI, Inc.: Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling | Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device.... ► Artikel lesen | |
| MANNKIND | 3,139 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| NEOVACS | 0,002 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| QIAGEN | 45,090 | +0,09 % | Neue Aufträge, neuer Aktionär, neues Gebot: Frische Fantasie bei HPQ Silicon, CTS Eventim und Qiagen | Erstellt und veröffentlicht im Auftrag von HPQ Silicon Manchmal genügt eine einzige Nachricht, um die Geschichte hinter einer Aktie neu zu schreiben. Bei HPQ Silicon sollen zertifizierte Hochleistungszellen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| ENLIVEN THERAPEUTICS | 44,250 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 18,155 | -0,14 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 126,72 | +0,07 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| TANGO THERAPEUTICS | 22,710 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| BAMBUSA THERAPEUTICS | 14,900 | -0,60 % | Bambusa Therapeutics, Inc.: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering | BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or " Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,025 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| SUMMIT THERAPEUTICS | 16,030 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| VOR BIOPHARMA | 19,680 | 0,00 % | Vor Bio Down on Q3 Results | ||
| KINIKSA PHARMACEUTICALS | 92,10 | -0,15 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| PRIME MEDICINE | 4,720 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen |
METIS TECHBIO CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,41 % bei einem Aktienkurs von 1,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu METIS TECHBIO CO LTD finden Sie auf Wallstreet Online.